Clinical Trials Browser

Phase 1/2 × alectinib × 90 days × Clear all

NCT05987644 2026-03-09

DURABLE

Phase 1/2 Recruiting

Brain Neoplasms, Lung Neoplasms

NCT04774718 2026-03-06

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Phase 1/2 Recruiting

Central Nervous System Neoplasms